What is Emyria?
Founded in 2018 and headquartered in Leederville, Australia, Emyria operates at the intersection of pharmaceutical innovation and patient-centric healthcare. The company distinguishes itself through a dual-track development strategy, focusing on the advancement of cannabinoid-based medicines alongside a sophisticated MDMA drug discovery program. By leveraging proprietary data and clinical insights, Emyria aims to navigate the complex regulatory landscape of modern medicine, providing evidence-based treatments for conditions that currently lack effective therapeutic options. Its market position is defined by a commitment to high-quality clinical trials and the pursuit of scalable, regulatory-approved pharmaceutical products.
How much funding has Emyria raised?
Emyria has raised a total of $2.5M across 1 funding round:
Share Placement
$2.5M
Share Placement (2023): $2.5M with participation from Sixty Two Capital
Key Investors in Emyria
Sixty Two Capital
Sixty-Two Capital is a corporate advisory and investment firm that specializes in providing strategic financial solutions to high-growth businesses across various industries, including healthcare and technology.
What's next for Emyria?
The recent infusion of capital serves as a critical catalyst for Emyria as it transitions into more advanced phases of its clinical development roadmap. Moving forward, the company is expected to prioritize the expansion of its MDMA-assisted therapy programs and the optimization of its cannabinoid-based medicine portfolio. By utilizing this strategic financing, Emyria intends to strengthen its operational infrastructure, enhance its research capabilities, and pursue key regulatory milestones. This trajectory suggests a focus on long-term value creation, as the firm seeks to translate its scientific breakthroughs into tangible, market-ready medical solutions that address significant gaps in the global healthcare sector.
See full Emyria company page
